Clinical and Experimental Reproductive Medicine

  • 제48권3호
  • /
  • Pages.268-272
  • /
  • 2021
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Birth of a healthy infant after bone marrow-derived cell therapy

  • Patel, Nayana H (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Jadeja, Yuvraj D (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Patel, Niket H (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Patel, Molina N (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Bhadarka, Harsha K (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Chudasama, Piyush N (Department of Reproductive Medicine, Akanksha Hospital and Research Institute) ;
  • Thakkar, Harmi R (Department of Reproductive Medicine, Akanksha Hospital and Research Institute)
  • 투고 : 2020.11.24
  • 심사 : 2021.05.17
  • 발행 : 2021.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bone marrow-derived cell (BMDC) therapy has numerous applications as potential biological cells for use in regenerative medicine. Here, we present an original case of endometrial atrophy associated with genital tuberculosis in a woman who achieved a live birth with BMDC. This 27-year-old woman came to our center with endometrial atrophy and primary infertility. She had a past history of genital tuberculosis and amenorrhea. Her husband's semen quality was normal. The patient was counseled for hysteroscopy due to thin endometrium and advised in vitro fertilization (IVF) with donor eggs in lieu of poor ovarian reserve. Several attempts of IVF with hormone replacement therapy (HRT) were made, but the desired thickness of the endometrium was not achieved. Uterine artery injection of BMDC through interventional radiology was given, followed by HRT for three months, which resulted in improved endometrium. This was subsequently followed by IVF with donor egg. The treatment resulted in the conception and delivery of a 3.1-kg baby boy through lower segment caesarean section with no antenatal, intranatal or postnatal complications. Recently, there has been massive interest in stem cells as a novel treatment method for regenerative medicine, and more specifically for the regeneration of human endometrium disorders like Asherman syndrome and thin endometrium, which was the reason behind using this strategy for treatment.

키워드

과제정보

Editorial support was provided by Dr. Manish Varma and Dr. Ravneet Gulshan from Spirant Communication Private Limited.

참고문헌

  1. Lee YJ, Yi KW. Bone marrow-derived stem cells contribute to regeneration of the endometrium. Clin Exp Reprod Med 2018;45:149-53. https://doi.org/10.5653/cerm.2018.45.4.149
  2. Santamaria X, Cabanillas S, Cervello I, Arbona C, Raga F, Ferro J, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod 2016;31:1087-96. https://doi.org/10.1093/humrep/dew042
  3. Dreisler E, Kjer JJ. Asherman's syndrome: current perspectives on diagnosis and management. Int J Womens Health 2019;11:191-8. https://doi.org/10.2147/IJWH.S165474
  4. Gargett CE, Healy DL. Generating receptive endometrium in Asherman's syndrome. J Hum Reprod Sci 2011;4:49-52.
  5. Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: a novel cell based therapy. J Hum Reprod Sci 2014;7:93-8. https://doi.org/10.4103/0974-1208.138864
  6. Sakr S, Naqvi H, Komm B, Taylor HS. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology 2014;155:1489-97. https://doi.org/10.1210/en.2013-1977
  7. Liu Y, Tal R, Pluchino N, Mamillapalli R, Taylor HS. Systemic administration of bone marrow-derived cells leads to better uterine engraftment than use of uterine-derived cells or local injection. J Cell Mol Med 2018;22:67-76. https://doi.org/10.1111/jcmm.13294
  8. Cervello I, Gil-Sanchis C, Santamaria X, Cabanillas S, Diaz A, Faus A, et al. Human CD133(+) bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome. Fertil Steril 2015;104:1552-60.e1-3. https://doi.org/10.1016/j.fertnstert.2015.08.032
  9. Azizi R, Aghebati-Maleki L, Nouri M, Marofi F, Negargar S, Yousefi M. Stem cell therapy in Asherman syndrome and thin endometrium: stem cell- based therapy. Biomed Pharmacother 2018;102:333-43. https://doi.org/10.1016/j.biopha.2018.03.091